Clinical Trial Update: Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN [Phase 3]

View source ↗

Summary

A Phase III clinical trial to evaluate the efficacy and safety of HSK39297 tablet in adults with primary IgA nephropathy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• HSK39297 Tablet (HSK39297)

Snippet

Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Conditions: IgA Nephropathy (IgAN) | Phase 3 | Status: RECRUITING